HOUSTON, March 19, 2024 /PRNewswire/
-- FibroBiologics, Inc., (Nasdaq: FBLG)
("FibroBiologics"), a clinical-stage biotechnology company
with 150+ patents issued and pending with a focus on the
development of therapeutics and potential cures for chronic
diseases using fibroblasts and fibroblast-derived materials,
announced the progress of a clinical program under development
using a fibroblast-based pancreatic beta cell spheroid that
secretes insulin in vitro upon glucose stimulation. The
development and reproducibility of this work demonstrates that an
organoid composed of fibroblasts, beta cells and other components
can successfully and durably secrete insulin.
"This early proof of concept is encouraging and may lead to a
new and durable potential allogeneic treatment option for people
with insulin-dependent diabetes," said Hamid Khoja, Ph.D., Chief Scientific Officer.
"We look forward to confirming these early results and in
vivo utility. We will then determine whether to designate the
program as an early phase pre-clinical project for developing a
minimally invasive therapeutic for type 1 diabetes."
About Diabetes
Diabetes mellitus is a chronic heterogeneous metabolic disease
characterized by elevated blood glucose levels due to abnormalities
in either insulin production or insulin action that impacts more
than 37 million people in the United
States and over 500 million people worldwide. Type 1
diabetes, an autoimmune disorder in which the immune system
destroys the pancreatic beta cells that produce insulin, accounts
for 10% of diabetes cases worldwide, and type 2 diabetes, in which
the body does not respond to insulin, accounts for the remaining
90% of diabetes cases. With such a high and growing prevalence of
the disease, over 200 million individuals are dependent on
consistent and often daily insulin therapy for their health. To
date, durable, long-term, and economical treatment options are not
available.
Cautionary Statement Regarding Forward-Looking
Statements
This communication contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include information concerning the
potential of organoids composed of fibroblasts, beta cells and
other components to successfully and durably secrete insulin and to
treat insulin-dependent diabetes, and our expectations regarding
plans for our current and future product candidates and programs.
These forward-looking statements are based on FibroBiologics'
management's current expectations, estimates, projections and
beliefs, as well as a number of assumptions concerning future
events. When used in this communication, the words "estimates,"
"projected," "expects," "anticipates," "forecasts," "plans,"
"intends," "believes," "seeks," "may," "will," "should," "future,"
"propose" and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements. These forward-looking
statements are not guarantees of future performance, conditions or
results, and involve a number of known and unknown risks,
uncertainties, assumptions and other important factors, many of
which are outside FibroBiologics' management's control, that could
cause actual results to differ materially from the results
discussed in the forward-looking statements, including those set
forth under the caption "Risk Factors" and elsewhere in
FibroBiologics' annual, quarterly and current reports (i.e., Form
10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC
and any subsequent public filings. Copies are available on the
SEC's website, www.sec.gov. These risks, uncertainties, assumptions
and other important factors include, but are not limited to: (a)
the ability of FibroBiologics to continue to meet Nasdaq listing
requirements; (b) risks related to FibroBiologics' liquidity and
its ability to maintain capital resources sufficient to conduct its
business; (c) the ability to effectively manage the business as a
result of the super-voting proxy given to the Board of Directors;
(d) expectations regarding the initiation, progress and expected
results of our R&D efforts and preclinical studies; and (e) the
unpredictable relationship between R&D and preclinical results
and clinical study results. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and FibroBiologics
assumes no obligation and, except as required by law, does not
intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise. FibroBiologics gives no assurance that it will achieve
its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a cell therapy and
regenerative medicine company developing a pipeline of treatments
and seeking potential cures for chronic diseases using fibroblast
cells and fibroblast-derived materials. FibroBiologics holds 150+
US and internationally issued patents/patents pending across
various clinical pathways, including disc degeneration,
orthopedics, multiple sclerosis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next
generation of medical advancement in cell therapy. For more
information, visit www.FibroBiologics.com.
Investor Relations:
Nic Johnson or Harrison Seidner, Ph.D.
Russo Partners
(646) 942-5599
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
General Inquiries:
info@fibrobiologics.com
Logo -
https://mma.prnewswire.com/media/1588786/4600873/FibroBiologics_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/fibrobiologics-announces-preliminary-proof-of-concept-for-fibroblast-based-diabetes-treatment-302092440.html